ArticleAging and disease2011
Immunity, cancer and aging: lessons from mouse models.
Article in Aging and disease, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 24 citations in OpenAlex.
- miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms.Blood · 2021Article
- Endurance Exercise Mitigates Immunometabolic Adipose Tissue Disturbances in Cancer and Obesity.International journal of molecular sciences · 2020Review
- The Impact of Age and Sex on Mouse Models of Melioidosis.Pathogens (Basel, Switzerland) · 2020Article
- IL-7-dependent compositional changes within the γδ T cell pool in lymph nodes during ageing lead to an unbalanced anti-tumour response.EMBO reports · 2019Article
- mTOR and Aging: An Old Fashioned Dress.International journal of molecular sciences · 2019Review
- A Novel Prognostic Nomogram for Predicting Risks of Distant Failure in Patients with Invasive Breast Cancer Following Postoperative Adjuvant Radiotherapy.Cancer research and treatment · 2018Article
- Inflammation is a key contributor to ovarian cancer cell seeding.Scientific reports · 2018Article
- Cancer Immunotherapies: Are They as Effective in the Elderly?Drugs & aging · 2017Review
- The combined molecular adjuvant CASAC enhances the CD8+ T cell response to a tumor-associated self-antigen in aged, immunosenescent mice.Immunity & ageing : I & A · 2015Article
- Article
- C/EBPα is dispensable for the ontogeny of PD-1+ CD4+ memory T cells but restricts their expansion in an age-dependent manner.PloS one · 2014Article
- Lnk deficiency partially mitigates hematopoietic stem cell aging.Aging cell · 2012Article
- Microarray analysis of ageing-related signatures and their expression in tumors based on a computational biology approach.Genomics, proteomics & bioinformatics · 2012Article
- Aging, cancer, and cancer vaccines.Immunity & ageing : I & A · 2012Article
- Is Immune Aging a Cause of Disease among the Elderly, or is it a Passive Indicator of General Decline of Physiologic Function?Aging and disease · 2011Article
- Can neutrophil to lymphocyte ratio predict lamina propria invasion in patients with non muscle invasive bladder cancer?International braz j urol : official journal of the Brazilian Society of UrologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The deterioration of immune function with advancing age is associated with an increased incidence of cancer. Most of the studies to evaluate the effect of immunotherapy on cancer have been conducted in the young without considering the effect of age-associated changes in immune function. Studies from my laboratory and others groups indicate that immunotherapeutic interventions could be effective in young animals, but that the same therapies are not as effective in old animals. The present review summarizes some defects found in the old immune system affecting the activation of antitumor immune responses, the strategies used to activate a more robust antitumor immune response in the old and the description of a preclinical tumor model indicating possible strategies for optimization of immunotherapeutic interventions in the old.
Indexed as
Identifiers
22396898PMC3295066W1564894628What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.